Loading
companiesCompany
IO Biotech
IO Biotech makes an off-the-shelf cancer vaccine that trains T cells to attack both tumour cells and the immune-suppressing cells around them. Its large melanoma trial narrowly missed its main goal in 2025 and the company is now reviewing its options.
Overview
IO Biotech (Nasdaq: IOBT), headquartered in Copenhagen with a US office in New York, develops immune-modulatory cancer vaccines on its T-win platform. Lead candidate Cylembio (IO102-IO103) stimulates T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and PD-L1 positive cells, aiming to kill both tumour cells and immune-suppressive cells in the tumour microenvironment. In the phase 3 IOB-013 trial in first-line advanced melanoma, Cylembio plus pembrolizumab gave median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab alone (hazard ratio 0.77, 95 percent CI 0.58 to 1.00, p=0.0558), narrowly missing the prespecified significance threshold of p≤0.045 (ESMO, October 2025). Five-year outcomes from the phase 1/2 trial were published in Nature Communications in December 2025. In January 2026 the company engaged Raymond James to explore strategic alternatives and announced a workforce reduction to preserve cash.
Headquarters
Copenhagen, DK
Scorecard
All companies#301of 1244 companies, score 14
- phase 3 +3
- targets +4
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 2 targets, 6 registry studies. Formula on the scorecards page.
Type
Biotech · IOBT
Stage
Public
Website
Phase 3peptide (immunotherapeutic vaccine)
IO102-IO103 is an experimental peptide (immunotherapeutic vaccine) from IO Biotech in phase 3 trials for melanoma and head and neck squamous cell carcinoma, aimed at PD-L1.
Notes
top- No financing round could be sourced from fetched pages. Outcome of the strategic review after January 2026 not verified. Founding year not sourced.
Similar pages
- TargetIDO1
Shares IO102-IO103, PD-L1, Melanoma.
- CompanyEvaxion
Shares Off-the-shelf cancer vaccines, Melanoma.
- PersonTasuku Honjo
- InstitutionThe Wistar Institute
Shares Off-the-shelf cancer vaccines, Melanoma.
- InstitutionUVA Comprehensive Cancer Center
Shares Off-the-shelf cancer vaccines, Melanoma.
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Off-the-shelf cancer vaccines, Melanoma.
- TreatmentT3011
- Key paperTumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge
cancers
fronts
technologies
targets
drugs
Phase 3peptide (immunotherapeutic vaccine)